文献速递传染病防控与疫情报告免疫规划

mRNA疫苗接种与轻症新冠患者新冠后状况患病率的相关性

The association between COVID-19 vaccination with the prevalence of post-COVID conditions in Thai patients with mild COVID-19.
PubMed 文献 · Vaccine · 2025-12-04

在泰国清迈Maharaj Nakorn医院开展的前瞻性队列研究纳入288例轻症新冠患者,随访至确诊后12-14周,新冠后状况(PCC)患病率为47.6%。至少接种一剂mRNA疫苗者PCC风险显著低于未接种者(43.5% vs 67.3%;OR 0.37,95%CI 0.20-0.71),三剂次保护作用最强(OR 0.27,95%CI 0.12-0.64)。

要点

  • 轻症新冠患者PCC患病率达47.6%,咳嗽和运动能力下降最常见。
  • 至少一剂mRNA疫苗与PCC风险降低相关(OR 0.37,95%CI 0.20-0.71)。
  • 三剂mRNA疫苗保护作用最强(OR 0.27,95%CI 0.12-0.64)。

核心结论

  • mRNA疫苗接种与轻症新冠患者发生新冠后状况的风险降低相关。

研究设计与样本

  • 2023年2月至12月在泰国Maharaj Nakorn Chiang Mai医院开展的前瞻性队列研究,纳入293例轻症新冠患者,最终分析288例。
  • 通过结构化访谈在确诊后4-6周和12-14周评估PCC症状,接种状态分为至少一剂mRNA疫苗或未接种mRNA疫苗。
  • 采用多因素logistic回归模型评估PCC危险因素。

主要发现

  • PCC患病率为47.6%,最常见症状为咳嗽(67.9%)和运动能力下降(21.2%)。
  • 至少接种一剂mRNA疫苗者PCC发生率43.5%,未接种者67.3%(OR 0.37,95%CI 0.20-0.71)。
  • 接种三剂mRNA疫苗者保护作用最强(OR 0.27,95%CI 0.12-0.64)。
  • 年龄、性别和合并症与PCC无显著关联。

临床怎么用

  • 在轻症新冠患者中,接种mRNA疫苗可能有助于降低PCC发生风险,三剂次接种保护作用更强。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-COVID conditions (PCC) have been reported in nearly half of individuals recovering from SARS-CoV-2 infection and are characterized by persistent symptoms, including fatigue, respiratory complaints, and reduced exercise capacity. While vaccines are known to reduce severe COVID-19, their potential to mitigate long-term complications remains less understood. Current studies often focus on severe COVID-19 cases, leaving a gap in understanding the benefits of vaccination in milder cases. This study investigated the association between mRNA vaccination and PCC risk, explored PCC prevalence and characteristics, and assessed potential risk factors in patients with mild COVID-19. METHODS: A prospective cohort study was conducted at Maharaj Nakorn Chiang Mai Hospital from February to December 2023. Among 293 enrolled patients, 288 were included in the final analysis after excluding those lost to follow-up. PCC symptoms were assessed via structured interviews at 4-6 and 12-14 weeks post-diagnosis. Vaccination status was categorized as having received at least one dose of mRNA vaccine or no mRNA vaccine. Multivariate logistic regression models were used to evaluate PCC risk factors. RESULTS: The prevalence of PCC was 47.6 %, with cough (67.9 %) and reduced exercise capacity (21.2 %) being the most common symptoms. Patients who received at least one mRNA vaccine dose were significantly less likely to develop PCC compared to unvaccinated individuals (43.5 % vs. 67.3 %; OR 0.37, 95 % CI 0.20-0.71). The strongest protective effect was observed in those receiving three doses (OR 0.27, 95 % CI 0.12-0.64). No significant associations were found for age, sex, or comorbidities. CONCLUSION: mRNA vaccination was associated with a reduced risk of PCC. These findings provide valuable insights into the potential benefits of mRNA vaccines in addressing long-term outcomes of COVID-19 in patients with mild disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Towachiraporn S, Thongwitokomarn H, Salee P, et al. The association between COVID-19 vaccination with the prevalence of post-COVID conditions in Thai patients with mild COVID-19. Vaccine. 2025. PMID: 41349444. doi:10.1016/j.vaccine.2025.128060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。